Neoadjuvant therapy for pancreatic cancer: the Duke experience.

Abstract

The advantages of neoadjuvant (preoperative) chemoradiation therapy for pancreatic cancer include the assurance that all resected patients receive multimodality therapy; the opportunity for patients with occult metastatic disease to manifest themselves; and the potential to improve resectability. Since 1994, Duke University Medical Center has treated over 180 patients with localized pancreatic cancer using neoadjuvant 5-fluorouracil (5FU)-based chemoradiation therapy (CRT). Approximately 20% of patients demonstrate distant disease progression during CRT and avoid the morbidity of laparotomy. Almost 20% of locally advanced tumors on initial-staging CT can be resected following CRT. Patients who have successfully undergone resection have experienced favorable survival with an estimated 5-year survival rate of 36%. This article reviews the authors' experience and the lessons learned from it.

Statistics

050'06'07'08'09'10'11'12'13'14'15'16'17
Citations per Year

183 Citations

Semantic Scholar estimates that this publication has 183 citations based on the available data.

See our FAQ for additional information.

Cite this paper

@article{White2004NeoadjuvantTF, title={Neoadjuvant therapy for pancreatic cancer: the Duke experience.}, author={Rebekah R White and Douglas S. Tyler}, journal={Surgical oncology clinics of North America}, year={2004}, volume={13 4}, pages={675-84, ix-x} }